1. Introduction

Bacteriophage therapy is a biotechnology-based medical treatment that uses bacteriophages (viruses that infect and destroy bacteria) to treat bacterial infections. It is particularly relevant to antibiotic-resistant infections, including multidrug-resistant bacterial diseases.

Russia has a significant historical and scientific connection with bacteriophage research. Russian and Soviet scientific institutions have investigated bacteriophages for therapeutic purposes for decades, particularly in relation to Staphylococcus, Streptococcus, Pseudomonas aeruginosa, Klebsiella and other bacterial infections.

However, bacteriophage therapy raises important legal questions concerning:

Classification of bacteriophages as medicinal products.

Clinical trials and regulatory approval.

Patient safety and informed consent.

Manufacturing and quality control.

Genetically modified bacteriophages.

Intellectual property and biotechnology patents.

Liability for treatment-related injuries.

Antibiotic resistance and public-health regulation.

An important legal distinction: Russia does not have a single comprehensive statute exclusively regulating bacteriophage therapy. Its regulation is derived from pharmaceutical, biotechnology, healthcare, clinical-trial, sanitary and civil-liability legislation.

2. Constitutional and statutory framework

The principal legal sources are the following.

The most important legislation is Federal Law No. 61-FZ.

Under Article 13, medicinal products generally require state registration before entering civil circulation. Articles 38–43 establish the framework for clinical trials and protections for participating patients.

WIPO+1

3. Legal classification of bacteriophage medicines

Bacteriophages are biological agents, but preparations intended for treating human disease fall within Russia's pharmaceutical regulatory framework.

Three important categories can be distinguished.

A. Standard bacteriophage preparations

These are commercially manufactured preparations containing specified bacteriophages or combinations of bacteriophages.

Examples include:

Staphylococcal bacteriophage.

Streptococcal bacteriophage.

Pseudomonas bacteriophage.

Klebsiella bacteriophage.

Intestiphage.

Pyophage.

Their manufacture, registration, labelling, storage and distribution must comply with applicable pharmaceutical requirements.

B. Experimental bacteriophage preparations

These are preparations under scientific investigation. Their use in clinical research must comply with the clinical-trial authorization, ethical review and patient-protection requirements of pharmaceutical law.

C. Personalized bacteriophage preparations

Personalized therapy involves identifying a patient's bacterial isolate and selecting or combining bacteriophages that demonstrate activity against that particular isolate.

This raises a difficult regulatory issue: changing the composition of a medicinal product may require a new or modified regulatory authorization.

A 2023 comparative scientific review describes Russia as prohibiting personalized bacteriophage therapy under its existing pharmaceutical framework. This should be understood as a description of the regulatory position discussed by the authors, rather than an independent statutory provision expressly using that wording.

Frontiers+1

4. State registration and pharmaceutical approval

Federal Law No. 61-FZ establishes the registration framework for medicines.

A bacteriophage manufacturer must address several regulatory requirements:

Identification and characterization of the bacteriophage strains.

Demonstration of microbiological purity.

Assessment of potency and biological activity.

Verification of product stability.

Appropriate safety and efficacy evidence.

Manufacturing quality assurance.

Compliance with approved product specifications.

The Russian Pharmacopoeia contains specific provisions concerning bacteriophage preparations, including GPM.1.8.1.0002.15, as discussed in the scientific literature.

The purpose of these requirements is to ensure that therapeutic preparations are sufficiently characterized and consistently manufactured.

Frontiers+1

5. Clinical trials and research regulation

Clinical research involving bacteriophage medicines must comply with Federal Law No. 61-FZ.

Article 38: Clinical trials

Clinical trials may investigate:

Safety and tolerability.

Appropriate dosage.

Therapeutic effectiveness.

Treatment duration.

Adverse reactions.

Additional medical indications.

The law requires the relevant authorization and the involvement of appropriately accredited medical institutions.

Article 39: International and multicentre trials

International multicentre and post-registration clinical trials also require the applicable regulatory authorization and ethical examination.

Article 43: Rights of patients

Participation must be voluntary. Patients must receive written information about the investigational medicine, anticipated benefits, risks, trial duration, insurance arrangements and confidentiality protections. Patients may withdraw from participation.

These provisions are especially important where bacteriophage treatment is investigated for infections that have not responded to conventional antibiotics.

WIPO+1

6. Informed consent and patient rights

Federal Law No. 323-FZ is central to patient protection.

Article 20 establishes the general framework for informed voluntary consent to medical intervention and refusal of medical intervention.

In bacteriophage therapy, consent should address:

The nature of the bacterial infection.

The proposed bacteriophage preparation.

Whether the treatment is registered for the proposed indication.

Expected benefits and scientific uncertainty.

Potential adverse effects.

Available alternative treatments.

The consequences of refusing treatment.

A doctor should not describe an experimental or unapproved treatment as an established cure.

A distinction must also be maintained between ordinary medical consent and the additional written consent required for participation in a regulated clinical trial.

7. Manufacturing and quality-control obligations

Manufacturing is one of the most important areas of bacteriophage law.

Bacteriophage preparations are biologically complex. Their activity can be affected by bacterial host selection, purification, storage conditions and changes in biological potency.

Manufacturers must establish appropriate controls covering:

Biological identity: The identity and characteristics of the selected bacteriophage must be established.

Purity: Production must control bacterial contaminants and residual manufacturing materials.

Potency: The preparation must meet its specified biological activity.

Stability: Storage and shelf-life conditions must be supported by appropriate testing.

Batch consistency: Each manufactured batch must comply with approved quality specifications.

Documentation: Manufacturing records must support traceability and regulatory inspection.

Federal Law No. 61-FZ, particularly its manufacturing provisions, is the principal statutory framework. Pharmaceutical licensing and applicable good manufacturing practice requirements are also relevant.

8. Regulation of genetically engineered bacteriophages

Modern biotechnology permits bacteriophages to be genetically modified to improve their therapeutic properties.

Potential modifications include:

Removing genes associated with lysogenic behaviour.

Modifying host-range characteristics.

Improving bacterial targeting.

Introducing genetic elements that affect bacterial resistance.

Developing CRISPR-enhanced bacteriophages.

These technologies raise additional legal issues involving genetic engineering, biosafety, environmental release and pharmaceutical quality.

Federal Law No. 86-FZ provides the Russian framework for state regulation of genetic engineering activities.

The regulatory assessment may depend on the nature of the genetic modification, the intended use, the production method and the possibility of environmental exposure.

A genetically modified bacteriophage intended for human treatment must also satisfy applicable pharmaceutical requirements. Genetic engineering compliance does not replace medicinal-product registration.

9. Antibiotic resistance and public-health governance

Bacteriophage therapy has particular importance in the fight against antimicrobial resistance.

Unlike conventional antibiotics, bacteriophages can selectively infect particular bacterial strains. However, their effectiveness depends on matching the phage to the bacterial target.

Russian public-health regulation therefore raises several questions:

How should resistant infections be identified?

Who is responsible for microbiological testing?

What standards should laboratories follow?

How should therapeutic failures be reported?

How should bacteriophage resistance be monitored?

What evidence is necessary before expanding approved indications?

A 2026 Russian-language scientific review discusses the potential role of phage therapy in generalized infections and identifies regulatory and technological obstacles, including the lack of authorized personalized selection mechanisms and limitations concerning intravenous preparations.

RUSMED

10. Judicial decisions and case-law analysis

An important research limitation must be stated: I have not verified a published Russian court judgment specifically concerning bacteriophage therapy. The following are therefore statutory and judicial principles applicable to potential disputes, not fabricated bacteriophage-specific precedents.

A. Pharmaceutical registration and regulatory disputes

Relevant law: Federal Law No. 61-FZ, Article 13.

A manufacturer challenging a refusal of registration or regulatory restriction could raise questions concerning:

Legality of the regulatory decision.

Scientific assessment of product safety.

Compliance with registration requirements.

Procedural fairness.

Whether the regulator acted within its statutory authority.

Legal significance: A bacteriophage preparation cannot ordinarily be marketed as a registered medicine merely because laboratory experiments demonstrate antibacterial activity.

B. Medical negligence and treatment-related injury

Relevant laws:

Federal Law No. 323-FZ.

Civil Code, Article 1064.

Suppose a physician administers a bacteriophage preparation without adequately assessing the patient's infection or the suitability of the preparation.

A civil claim could examine:

Whether a professional duty existed.

Whether the physician breached that duty.

Whether the treatment caused the injury.

Whether the patient suffered compensable damage.

Legal significance: Medical professionals and healthcare institutions may face liability where negligent conduct causes injury.

C. Defective pharmaceutical products

Relevant law: Civil Code, Articles 1095–1098.

Suppose a commercially distributed bacteriophage preparation contains contamination or fails to satisfy its applicable quality specifications.

Potential claims may concern:

Defective pharmaceutical quality.

Inadequate product information.

Manufacturing negligence.

Causation of patient injury.

Compensation for resulting losses.

These provisions provide a potential framework for product-liability litigation.

D. Informed-consent litigation

Relevant law: Federal Law No. 323-FZ, Article 20.

If a patient is not informed that a proposed bacteriophage treatment is experimental or carries significant uncertainties, a dispute may arise over the validity of consent and the healthcare provider's obligations.

Legal significance: Consent must be informed and voluntary. A signed document does not automatically establish that all disclosure obligations were satisfied.

E. Intellectual-property disputes

Relevant legislation: Part IV of the Civil Code of the Russian Federation.

Disputes may concern:

Patents for genetically modified bacteriophages.

Patent protection for therapeutic compositions.

Ownership of biotechnology inventions.

Licensing agreements.

Confidential bacterial and phage databases.

Commercial exploitation of research results.

These disputes would generally be resolved through the ordinary Russian intellectual-property framework.

11. Important scientific and regulatory developments

Phages Attack # A History of Bacteriophage Production and Therapeutic Use in Russia

Russian bacteriophage research tradition

Russia has a longstanding history of commercial bacteriophage preparations and therapeutic research.

Пиобактериофаг поливалентный очищенный | АО НПО Микроген

NPO Microgen

A significant Russian manufacturer associated with commercially available bacteriophage preparations.

Frontiers+1

Bacteria-hunting viruses help diagnose and treat UTIs

Personalized phage therapy

Scientific developments create pressure for regulatory systems to accommodate individually selected and changing phage compositions.

12. Major legal challenges

13. Recommendations for reform of Russian bacteriophage law

Several reforms could improve the legal framework.

1. Personalized bacteriophage authorization

Russia could establish a regulated pathway for personalized preparations, subject to strict microbiological testing, quality assurance and clinical oversight.

2. Adaptive registration

A regulatory system could permit controlled modifications to approved bacteriophage cocktails without requiring an entirely new registration for every scientifically justified change.

3. Dedicated clinical-trial standards

Specific standards should address phage susceptibility testing, bacterial resistance, pharmacokinetics, safety monitoring and treatment effectiveness.

4. Genetically engineered phage regulation

Additional guidance should clarify biosafety assessment, environmental risks, genetic stability and the regulatory classification of engineered phages.

5. Patient protection

Patients should receive clear information about treatment status, available alternatives, potential benefits and scientific uncertainties.

6. International cooperation

Russian regulators could cooperate with international scientific and pharmaceutical authorities to develop common quality and safety standards.

The European Medicines Agency's guidance on the quality aspects of phage therapy medicinal products provides a useful comparative reference for manufacturing, characterization and quality control.

European Medicines Agency (EMA)

14. Conclusion

Biotechnology bacteriophage therapy law in Russia operates at the intersection of pharmaceutical regulation, biotechnology, medical law, public-health governance and civil liability.

Federal Law No. 61-FZ is the principal legislation governing the registration, manufacture and clinical investigation of therapeutic bacteriophage products. Federal Law No. 323-FZ protects patients, while genetic-engineering, sanitary and civil-liability legislation addresses additional risks.

Russia's established bacteriophage industry provides a foundation for therapeutic applications, particularly against antibiotic-resistant bacterial infections. Nevertheless, personalized treatment, genetically engineered phages, changing cocktail compositions and the need for stronger clinical evidence present significant regulatory challenges.

The central legal question is how Russia can encourage bacteriophage innovation while ensuring pharmaceutical quality, scientific reliability, patient safety and accountability.

15. Important references and research sources

Federal Law No. 61-FZ – On Circulation of Medicines (WIPO Lex).

Regulations of Phage Therapy Across the World – Frontiers in Microbiology (2023).

Phages Connect the Biological Dots of Antimicrobial Resistance – Journal of Antimicrobial Chemotherapy.

EMA Guideline on Quality Aspects of Phage Therapy Medicinal Products.

Russian scientific review: Bacteriophages in generalized infections (2026).

Academic research note: The statutory framework is identifiable, but a dedicated body of reported Russian bacteriophage-therapy case law has not been established by the sources reviewed here. For legal citation in a dissertation or court submission, the latest consolidated Russian legislation, official State Register of Medicines and verified court decisions should be checked.